Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IFF

This article was originally published in The Rose Sheet

Executive Summary

Richard Furlaud named International Flavors & Fragrances interim president upon Chairman, President and CEO Eugene Grisanti's immediate retirement. Grisanti served as CEO for the fragrance supplier for 15 years and as an executive officer for 40 years. Furlaud is a former Bristol-Myers Squibb president and has been an IFF director since 1990. Grisanti announced his intention to retire in November. Heidrick & Struggles will review internal and external candidates

You may also be interested in...



IFF CEO Goldstein Takes Helm To Steer Supplier Into Calmer Waters

International Flavors & Fragrances CEO Richard Goldstein will unveil a strategic plan to drive top line growth while enhancing shareholder value, the newly appointed exec announced during a conference call April 26. The former Unilever president takes the helm June 1.

IFF CEO Goldstein Takes Helm To Steer Supplier Into Calmer Waters

International Flavors & Fragrances CEO Richard Goldstein will unveil a strategic plan to drive top line growth while enhancing shareholder value, the newly appointed exec announced during a conference call April 26. The former Unilever president takes the helm June 1.

IFF CEO Appointed From Outside Before May Annual Meeting

International Flavors & Fragrances expects to name a new CEO before the supplier's May 18 annual meeting, "but hopefully sooner," CFO Douglas Wetmore announced during a Jan. 27 conference call.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS007493

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel